osimertinib

Business

TAGRISSO ® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

‹‹‹First and only EGFR inhibitor and targeted treatment to show benefit in Stage III setting, extending progression-free survival by more…

Read More »
Back to top button